SCHEMBL24075249

SCHEMBL24075249

COC(=O)c1ccc(-c2nc3cc(F)c(F)cc3[nH]2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHEB Q15382 1/20 0.73
MMP2 P08253 1/20 0.67
MMP9 P14780 1/20 0.67
MMP8 P22894 1/20 0.67
MMP13 P45452 1/20 0.67
KDM4E B2RXH2 2/20 0.66
ALDH1A1 P00352 2/20 0.66
HPGD P15428 2/20 0.66
SMN1; SMN2 Q16637 2/20 0.66
NPC1 O15118 1/20 0.66
LMNA P02545 1/20 0.66
PKM P14618 1/20 0.66
NFKB1 P19838 1/20 0.66
RAB9A P51151 1/20 0.66
NFKB2 Q00653 1/20 0.66
RELA Q04206 1/20 0.66
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25723465 0.91 RHEB (0.61) RHEBMMP2MMP9MMP8MMP13
SCHEMBL25722556 0.86 RHEB (0.55) RHEBMMP2MMP9MMP8MMP13
SCHEMBL20982713 0.85 KDM4E (0.75) RHEBMMP2MMP9MMP8MMP13
SCHEMBL25318263 0.85 KDM4E (0.75) RHEBMMP2MMP9MMP8MMP13
SCHEMBL29906102 0.85 KDM4E (0.75) RHEBMMP2MMP9MMP8MMP13
SCHEMBL5651925 0.84 RHEB (1.00) RHEBMMP2MMP9MMP8MMP13
SCHEMBL24074305 0.83 NR4A2 (0.68) RHEBMMP2MMP9MMP8MMP13
SCHEMBL20982471 0.83 MMP2 (0.78) RHEBMMP2MMP9MMP8MMP13
SCHEMBL5222037 0.82 MMP2 (0.75) RHEBMMP2MMP9MMP8MMP13
SCHEMBL14381943 0.82 KDM4E (0.70) RHEBMMP2MMP9MMP8MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192626-A1 NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF BAYLOR COLLEGE OF MEDICINE (US) 2023-06-22 US disclosed
US-20230192626-A1 NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF BAYLOR COLLEGE OF MEDICINE (US) 2023-06-22 US disclosed
US-20230192626-A1 NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF BAYLOR COLLEGE OF MEDICINE (US) 2023-06-22 US disclosed
WO-2021242790-A1 NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF BAYLOR COLLEGE OF MEDICINE (US) 2021-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192626-A1 NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF EPHX1, EPHX2, NCEH1 RHEB 1868/4885MMP2 257/4885MMP9 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.